There are very few drug delivery systems that target key organs via the oral route, as oral delivery advances normally address gastrointestinal drug dissolution, permeation and stability. Here we introduce a nanomedicine, in which nanoparticles, while also protecting the drug from gastric degradation, are taken up by the gastrointestinal epithelia and transported to the lung, liver and spleen, thus selectively enhancing drug bioavailability in these target organs and diminishing kidney exposure (relevant to nephrotoxic drugs). Our work demonstrates, for the first time, that oral particle uptake and translocation to specific organs may be used to achieve a beneficial therapeutic response. We have illustrated this using amphotericin B, a nephrotoxic drug encapsulated within N-palmitoyl-N-methyl-N,N-dimethyl-N,N,N-trimethyl,6-Oglycolchitosan (GCPQ) nanoparticles and have evidenced our approach in three separate disease states (visceral leishmaniasis, candidiasis and aspergillosis) using industry standard models of the disease in small animals. The oral bioavailability of AmB-GCPQ nanoparticles is 24%. In all disease models, AmB-GCPQ nanoparticles show comparable efficacy to parenteral liposomal AmB (Ambisome®). Our work thus paves the way for others to use nanoparticles to achieve a specific targeted delivery of drug to key organs via the oral route. This is especially important for drugs with a narrow therapeutic index.
Introduction
The oral administration of medicines is a preferred route of administration although a significant proportion of drugs are not orally bioavailable due to their physical properties, an issue which contributes to 40% of drug development failures 1 . An industry, such as the pharmaceutical industry, which experiences 90% of clinical stage failures 2 and thus has to spend upwards of US$ 1 billion to develop a single new chemical entity medicine, requires new technologies that will enable medicine administration via the preferred route, regardless of the chemical features of any promising compounds. Oral drug delivery advances, to date, have focused on gastrointestinal drug dissolution 3 , gastrointestinal drug permeability 4 and gastrointestinal compound stability 5 .There are no technologies which have as their goal specific organ targeting via the oral route. Our central hypothesis is that nanoparticles which target specific organs via the oral route will confer oral activity on drugs which are not otherwise active through this route. Targeting particular organs of pathology and avoiding sites of toxicity is the goal of drug delivery. Here we present a nanoparticle system that allows oral targeting to the organs of pathology, i.e. the lung, liver and spleen, via the oral route but avoids delivery to the organs of toxicity, the kidneys. Such a system will be of particular relevance to nephrotoxic drugs. The utility of the system is illustrated via the use of amphotericin B (AmB), one of the most effective antifungal drugs used for the treatment of life-threatening systemic fungal infections such as candidiasis or aspergillosis and a drug that is also indicated for the treatment of visceral leishmaniasis 6, 7 ; the latter due to its very high cure rate and near absence of resistance.
Intravenous administration of AmB marketed formulations (Fungizone ® , Ambisome ® , Abelcet ® and Amphocil ® ) results in high drug levels in the target organs, i.e. the liver, spleen and lungs but also results in drug accumulation in the kidney, leading to toxicity, as the drug is nephrotoxic. Both nephrotoxicity and infusion-related side effects, such as infections, thrombophlebitis, fever, chills, vomiting, headaches and haemolysis limit the usefulness of parenteral AmB formulations. Furthermore, the requirement for hospitalisation during treatment, hampers access to parenteral AmB, especially in low resource environments such as developing countries 7, 8 . To date, no oral AmB formulations have been marketed because of AmB's poor gastrointestinal solubility and permeability 9, 10 . Therefore, developing an oral AmB formulation is a viable means of improving patient access to treatment worldwide.
N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) is a self-assembling nanoparticle forming polymer that is taken up by enterocytes and enables the bioavailability of hydrophobic drugs and peptides [11] [12] [13] [14] . Our oral drug organ targeting hypothesis will be tested by encapsulating AmB in GCPQ nanoparticles and studying drug and particle biodistribution and drug pharmacological efficacy in comparison to control nanoparticle systems: i.e., AmB liposomes (Ambisome ® ) or AmB deoxycholate micelles (AMBd).
Experimental section

Polymer synthesis and characterization
GCPQ and deuterated GCPQ were synthesized and characterised as previously described 11-13, 15, 16 . Nuclear Magnetic Resonance ( 1 H NMR) experiments were performed to determine the degree of substitution of the polymer. The level of palmitoylation was calculated as the ratio between palmitoyl methyl protons (δ= 1.30- 
Preparation, characterization, dissolution and stability studies of AmB-
GCPQ nanoparticles
Polyelectrolyte complex formation. AmB was solubilised through the formation of carboxylate salts at the concentration of 4 mg mL -1 in sodium hydroxide (0.02 N) at pH 12. GCPQ (20 mg mL -1 ) was added to the solution. Polyelectrolyte complexes were formed between the carboxylic groups of the AmB and the positively charged quaternary ammonium groups of the GCPQ. The final pH of the dispersion was reduced to pH = 5. AmB-GCPQ nanoparticles were centrifuged (13000 rpm, 30 positioned at the inner top of the cell to retain undissolved material. The dissolution medium was circulated by pumping it through the cell at a flow rate of 6 ml min -1 .
Three dissolution media prepared as described in the US Pharmacopeia 18 were used during the experiment: simulated gastric fluid without enzymes (pH = 1.2) from 0 to15 min, acetate buffer (pH = 4.5) from 15 to 30 min and simulated intestinal fluid without enzymes (pH = 6.8) from 30 to 240 min. The temperature was maintained at 37 ± 0.5°C during testing. Samples were collected from the flow-through cell in fractions and scanned between 300 -450 nm (Shimadzu UV-1700 spectrophotometer, Shimadzu, Kyoto, Japan). Calibration curves were prepared using each of the dissolution media. (at 1 mg mL -1 ) and drug content and particle size were recorded (please see
Supplementary Information for method details).
Pharmacokinetic studies in murine model
All experiments were performed under a UK Home Office Animal License. 
Oral pharmacokinetic studies in beagles
All experiments were approved and performed in accordance with local ethics committee rules (University Cardenal Herrera-CEU, Valencia, Spain). Infection. The preparation of the parasites and the experimental infection were performed as previously described 19 . Please see Supplementary Information for further details. Each animal was infected with 10 7 promastigotes by intracardiac injection. Plasma was separated by centrifugation and then both the plasma and kidneys were stored at -20 ºC until they could be analysed.
Animals
Tissue burden. The parasite burden was quantified by the limit dilution assay as described previously 20, 21 . Please see Supplementary Information for further details.
The percentage suppression of parasite replication (PS) was calculated using the following modified equation of Manandhar et al. 22 :
where PC is the number of parasites in the control group per tissue weight (g) and PT is the number of parasites after treatment per tissue weight (g).
Pharmacokinetic studies. Plasma and kidney samples were analysed as described above for the quantification of AmB in tissues. Tissue burden. Mice were sacrificed by chloroform inhalation at day 10 post-infection and target organs (kidneys, liver, lung, brain and spleen) were removed aseptically, weighed, and homogenized in sterile saline (5 ml g -1 tissue). The number of CFU was determined by a plate dilution method in duplicate using yeast extract dextrose chloramphenicol agar and colony counting was performed after 72 h of incubation at 30
Efficacy study in a systemic
°C.
Toxicological and pharmacokinetic studies. Blood samples were collected at day 10 post-infection and serum was separated by centrifugation (3000 rpm, 10 min, 4°C).
Samples were stored at −20°C for biochemistry analysis including creatinine, urea, alkaline phosphatase, aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin. Samples from healthy mice were included as controls. For pharmacokinetic studies, AmB concentrations in kidney, liver, brain and spleen were determined.
Statistical analysis
Statistical analyses were performed via one-way ANOVA Test using Minitab 15
(Minitab Ltd, Coventry, UK) followed by Tukey's test. Statistical significance was set at a p < 0.05. In aqueous environments, GCPQ self-assembles to form polymeric micelles with a particle size of between 5 -30 nm in diameter while AmB itself aggregates forming insoluble polyhedral crystals (see Supplementary Information Figure S2 ). The AmB, GCPQ interaction resulted in the solubilisation of AmB crystals followed by the formation of highly stable nanoparticles characterised by a particle size of 216 and 35 nm ( Figure 1b) . The biomodal size is due to an equilibrium being established between drug filled particles and empty micelles. The particles have a core shell structure with the ionic units (and hence dark stained areas) forming the particle shells and the hydrophobic groups (white stain free areas) forming the particle core (Figure 1 b) . The polar head of the AmB molecules will be oriented to the aqueous phase and the hydrophobic tail to the core of the nanoparticles. The hydrophobic tail of the polymer has the same number of carbons as the hydrophobic domain of AmB which should enhance the hydrophobic interaction (see Supplementary Information Figure S2 ). The amount of amphotericin B loaded in nanoparticles was 90% as quantified in the supernatant obtained after centrifugation. Dimers and monomers of AmB were encapsulated in the polymer exhibiting characteristic absorption peaks at 328, 363, 383
and 407 nm and resulting in a transparent yellow liquid 7 .
Lyophilised AmB-GCPQ nanoparticles exhibited good long term stability when stored at 5 ± 3 °C (particle size and drug content remained unaltered over one year, See
Supplementary Information Figure S3 ) and these particles significantly enhanced AmB dissolution in simulated gastrointestinal fluids when compared to AMBd (Figure 1c ). Tables S1 and S2 . With all formulations AmB plasma concentrations increased slowly and were sustained for 8 h after (Figure 2a ). However the drug was largely tissue bound and accumulated in the liver, spleen and lung ( Figure   2b, 2c, 2d) . AmB-GCPQ resulted in higher plasma levels when compared to AmB in dextrose. Significantly higher AmB levels were found in the liver when the particulate formulations of AmB (AmB -GCPQ and AMBd) were administered compared to AmB in dextrose (Figure 2b ). Significantly higher levels of AmB were found in the lungs and spleen, after oral administration of AmB-GCPQ compared to the administration of AmB in dextrose and AMBd. Only minor differences were found in AmB kidney levels, with respect to the formulation administered ( Figure 2e ). As AmB is a nephrotoxic drug, target organ, kidney ratios are crucial. Lung, kidney AUC0-24 ratios for AmB-GCPQ and AMBd were 1.44 and 0.86 respectively while the corresponding spleen, kidney ratios were 1.22 and 0.81 respectively and the corresponding liver, kidney ratios were 0.88 and 0.40 respectively. These data demonstrate that, when compared to the deoxycholate micelles, GCPQ nanoparticles delivered relatively more drug to the target organs (liver, lung and spleen) than was delivered to the kidney. This finding is further confirmed by lower urine levels of AmB with the oral AmB-GCPQ formulation (Supplementary Information Figure S4a ).
The AmB in dextrose formulation delivered the most drug to the kidneys at the early time points, showing the drug in solution is rapidly eliminated by the kidneys; a fact that could contribute to the occurrence of nephrotoxicity and would explain the reduced drug levels in the target organs with the AmB in dextrose formulation. AmB was also recovered from the gall bladder, reaching a maximum concentration at 4 hours following oral administration (see Supplementary Information Figure S4b ). This is evidence of enterohepatic circulation of the drug. After 4 h, AmB levels in the bile decreased as a result of the animals being fed. The percentage of the AmB dose recovered from tissues (liver, spleen, lungs, kidneys) and plasma, 8 h after dosing the AmB-GCPQ formulation was 2.3%, which is 2-fold higher than when the drug was administered orally in dextrose.
After the administration of multiple doses of AmB-GCPQ to mice, AmB accumulated in the target organs (lungs, liver and spleen) and to a lesser extent in the kidney ( Figure   2f and Supplementary Information Table S2 ). AmB-GCPQ also delivered AmB to the bone marrow and brain; the former important for the clearance of Leishmania and the latter important for the targeting of systemic fungal infections. AmB bile levels, following multiple doses, were significantly enhanced when compared to urine levels, further confirming a major role for enterohepatic circulation in AmB-GCPQ's delivery mechanism.
When a single dose of AmB-GCPQ was administered to dogs, again oral absorption was sustained for up to 8 h (Figure 2g ). Plasma levels in dogs with oral AmB-GCPQ were over two fold higher than plasma levels seen with the oral administration of a nanoparticle formulation -AmBisome ® . With AmB-GCPQ the plasma half-life (t1/2) was 59.2 h in dogs and drug was still detectable in the plasma 48 h after dosing, whereas it was not detectable 48 h after dosing with oral AmBisome ® in dogs. Both formulations were well tolerated and there were no signs of gastrointestinal toxicity (vomiting or diarrhoea).
After i.v. administration of AmB-GCPQ (Figure 2 h ), there was a fast decline in the AmB plasma level, followed by a slower disappearance of the drug from the plasma compartment as it equilibrates with the tissue bound drug. Similar high AmB tissue distributions have been observed by others 23, 24 . The absolute oral bioavailability of AmB-GCPQ was 24.7%. Similar oral bioavailability values have been reported for plain GCPQ nanoparticles 16 . The plasma t1/2 of the AmB-GCPQ formulation in mice was 61.3
h. 
Oral Particle Translocation to Major Organs
The coherent anti-stokes Raman spectroscopy (CARS) method used, images highly concentrated species in a narrow focal area and only reports a signal for a self- ) ii and iii were taken at the surface of the Peyer's patch, with M-cells and goblet cells marked with 'M' and 'G' respectively on B. iv was taken 14 microns below the surface, in the region outlined with a yellow box on iii. The cell outlined with a yellow box in iv is shown in more detail in v and vi, in three-dimensional composites of the CARS depth stack, illustrating the distribution of dGCPQ within this cell.
Efficacy in visceral leishmaniasis
The oral administration of AmB-GCPQ nanoparticles at 5 mg kg 
Efficacy in systemic candidiasis
Although AmB levels in tissues (kidney, liver, spleen and brain) after 9 days of parenteral Ambisome ® (at 3 mg kg -1 day -1 ) were significantly higher than those obtained after 9 days of oral AmB-GCPQ (at 5 mg kg -1 day -1 ) (Figure 6b ), no significant differences were found in the reduction of fungal burden (Figure 6a and b) between both therapies. Oral AmB-GCPQ (at 5 mg kg -1 day -1 ) cleared the spleen and liver and reduced by 1.4 log10 the fungal load in the brain compared to control animals.
The infected control group exhibited the highest levels of creatinine and urea as C.
albicans infection is associated with renal failure 25 ( Figure 6c and d) . For example, mice with the highest CFU in kidney (mice 1, 2 and 4) exhibited the highest urea and creatinine levels. Oral administration of AmB-GCPQ resulted in a reduction of urea levels compared to the infected control group but produced a significant increase in alkaline phosphatase levels (Figures 6c and h ). No significant differences were observed among the other biochemical parameters (Figures 6e -g ). 
Discussion
This is the first report in which orally administered nanoparticles (AmB-GCPQ) resulted in drug targeting to specific organs such as lung and spleen (Figures 2c, 2d and   3b ). While both particle formulations (AmB-GCPQ and AMBd), deliver higher levels of drug to the liver (Figure 2b and Figure 3a) , only the AmB-GCPQ formulation delivered drug specifically to the lung and spleen, while sparing of the organ of toxicity -the kidney (Figure 2e ). This targeting to key organs (essentially to the lungs, liver and spleen) is of benefit to the treatment of a number of infectious diseases such as visceral leishmaniasis ( Figure 4 ) and systemic fungal infections (Figures 5 and 6) , with a drug such as AmB, which is a broad spectrum anti-fungal and low resistance anti-leishmanial drug but which is severely nephrotoxic. One aspect that contributes to the utility of the nanoparticles is the exceptional stability of the AmB-GCPQ nanoparticles. AmB-GCPQ nanoparticles are stable for one year on storage (Supplementary Information Figure S3 ). AmB-GCPQ nanoparticles are formed via electrostatic interactions between the AmB carboxylate and GCPQ quaternary ammonium groups (Figure 1a) as well as via the hydrophobic attractions between the palmitoyl chains of the GCPQ molecule and long chain alkene groups of the AmB molecule. The net result is a formulation of exceptional stability, in which nanoparticles may be reconstituted from a dry powder (Supplementary Information Figure S3c ).
AmB-GCPQ nanoparticles enhanced the oral absorption of AmB when compared to the drug alone or to the reference particulate formulation AMBd. AmB is poorly soluble in aqueous media (< 1 mg L -1 ) 7 and its poor dissolution rate within the gastrointestinal tract will limit absorption as will its poor gut permeation, since AmB is a Biopharmaceutical Classification System Class IV drug with poor gut permeability as well as poor aqueous solubility 26 . AMBd formulations will provide an increase in dissolution rate as AmB is encapsulated within small, high surface area deoxycholate micelles, however AmB-GCPQ nanoparticles will not only increase drug dissolution but will also be taken up via the gut enterocytes and Peyer's patches (Figures 3c and e) thus solving the gut permeation problems associated with AmB. GCPQ nanoparticles are positively charged and are known to be mucoadhesive 12 , and taken up by the gut enterocytes with a bioavailability of 24% 13, 16 and now we also know that they are taken up by the Peyer's patches (Figure 3e ). Transport from the gut associated lymphoid tissue via the lymphatic vessels to the systemic circulation will also increase the oral bioavailability of the AmB-GCPQ formulation.
In comparison to other oral AmB lipid-based formulations that have been reported [27] [28] [29] , AmB-GCPQ nanoparticles are able to deliver greater amounts of drug to tissues after administering the same oral dose (5 mg kg -1 twice daily for 5 days); drug levels are 6.6 - 
Conclusions
In summary, our work demonstrates, for the first time, that oral particle uptake and translocation to specific organs may be used to achieve a beneficial therapeutic response. We have designed an orally active nanomedicine based on an amphiphilic nanoparticle forming polymer (GCPQ), which achieves a relative AmB oral bioavailability of 24.7%. AmB-GCPQ nanoparticles target AmB to particular organs of pathology and spare the site of toxicity -the kidney, resulting in effective treatments in preclinical disease models. This is the first report of a therapeutic advantage stemming directly from particle gut uptake and translocation to key organs of pathology. AmB liver, spleen and lung levels after oral AmB-GCPQ administration were lower than those obtained with parenteral formulations, however oral AmB-GCPQ was as effective as the parenteral AmBisome ® formulation in the treatment of visceral leishmaniasis, aspergillosis and systemic candidiasis animal models of these diseases.
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